About Covis Pharma
Covis Pharma is a company based in Zug (Switzerland) founded in 2011 was acquired by Azurity Pharmaceuticals in March 2025. The company has 10 employees as of December 31, 2020. Covis Pharma has completed 1 acquisition, including AMAG Pharma. Covis Pharma offers products and services including Alvesco, Duaklir, Feraheme, and Tudorza.
- Headquarter Zug, Switzerland
- Employees 10 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amag Pharmaceuticals Inc.
-
Annual Revenue
$474 M (USD)-4as on Dec 31, 2018
-
Net Profit
-$65.76 M (USD)67as on Dec 31, 2018
-
EBITDA
-$47.05 M (USD)85as on Dec 31, 2018
-
Latest Funding Round
$350 M (USD), Debt – Conventional
Dec 13, 2018
-
Investors
Apollo Global Management
& 2 more
-
Employee Count
10
as on Dec 31, 2020
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Covis Pharma
Covis Pharma offers a comprehensive portfolio of products and services, including Alvesco, Duaklir, Feraheme, and Tudorza.
Treats asthma and respiratory conditions through inhalation therapy.
Manages chronic obstructive pulmonary disease symptoms effectively.
Provides iron treatment for anemia in chronic kidney disease patients.
Controls symptoms of chronic bronchitis and emphysema conditions.
People of Covis Pharma
Unlock access to complete
Funding Insights of Covis Pharma
Investors in Covis Pharma
Covis Pharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Apollo Global Management, Azurity Pharmaceuticals and Cerberus Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Buyouts are targeted through private equity investments by the firm.
|
Locked | Locked | Locked | |
|
Private equity and debt firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Generic drugs are manufactured by Azurity Pharmaceuticals in the US.
|
Locked | Locked | Locked |
Investor details for Covis Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Covis Pharma
Covis Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AMAG Pharma.
Investment portfolio details for Covis Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufacturer of anemia based products and imaging agents for cancer and CVD diagnosis
|
Locked | Locked | 1981 | Locked |
Complete acquisition details for Covis Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Covis Pharma
Detailed financials for Covis Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Covis Pharma Comparisons
Peer comparison for Covis Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Covis Pharma
Detailed competitors of Covis Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Covis Pharma
Complete news archive for Covis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Covis Pharma
Covis Pharma was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Covis Pharma is headquartered in Zug, Switzerland. It is registered at Zug, Zug, Switzerland.
As of Dec 31, 2020, the latest employee count at Covis Pharma is 10.
Annual revenue of Covis Pharma is $474M as on Dec 31, 2018.
Covis Pharma was founded in 2011 in Zug, Switzerland, as a pharmaceutical company focused on the sector of treatments for severe health issues. A portfolio of five products, including Altoprev, Betapace, Betapace AF, Rilutek for amyotrophic lateral sclerosis, and Lanoxin injection for moderate heart failure, is maintained. Operations involve marketing these therapies internationally. In April 2015, 18 products were acquired by Concordia Healthcare Group for 1.2 billion.
Covis Pharma offers Alvesco, Duaklir, Feraheme, and Tudorza.
Covis Pharma has made 1 acquisition, including AMAG Pharma.
Covis Pharma has 3 investors. Key investors include Apollo Global Management, Azurity Pharmaceuticals, and Cerberus Capital Management.